{"id":20794,"date":"2024-06-25T08:51:21","date_gmt":"2024-06-25T06:51:21","guid":{"rendered":"https:\/\/ela-international.preprod.melisagency.fr\/?post_type=news_research&p=20794"},"modified":"2024-07-11T11:53:34","modified_gmt":"2024-07-11T09:53:34","slug":"evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy","status":"publish","type":"news_research","link":"https:\/\/elainternational.eu\/en\/actualites_recherche\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\/","title":{"rendered":"Evaluating glial and neuronal GFAP, MCP-1 and NfL as blood biomarkers for onset and disease severity in cerebral adrenoleukodystrophy"},"content":{"rendered":"\n\n
\n
\n
\n

Evaluating glial and neuronal GFAP, MCP-1 and NfL as blood biomarkers for onset and disease severity in cerebral adrenoleukodystrophy<\/strong><\/h3>\n <\/div>\n <\/div>\n<\/section>\n\n\n
\n
\n

Johannes Berger – Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Austria ELA2020-003C1<\/em><\/p>\n <\/div>\n<\/section>\n\n\n\n\n\n

\n
\n
\n
Description of the project<\/strong><\/h5>\n <\/div>\n
\n

With a combined incidence of 1:14,700, X-ALD is the most common monogenetically inherited leukodystrophy. The disease is caused by mutations of the peroxisomal very long-chain fatty acid transporter ABCD1 that normally imports very long-chain fatty acids into the peroxisome for degradation. Accordingly, loss of ABCD1 function results in accumulation of very long-chain fatty acids in the plasma and body fluids of affected patients. X-ALD shows a striking phenotypic heterogeneity with inflammatory cerebral X-ALD (CALD) being the most severe form. In order to be treatable by bone marrow transplantation or gene therapy, CALD has to be recognized in its earliest stages.<\/p>\n

The ultimate goal of this research project is to identify an easily accessible blood biomarker indicative for onset and progression of CALD. If successful, the identified blood biomarker could provide valuable information for decisions on clinical interventions and could also be used as treatment efficacy marker in clinical trials targeting CALD.<\/p>\n

Project financed by ELA up to:\u00a029 000 \u20ac<\/p>\n <\/div>\n <\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"template":"","news_research_categories":[127],"news_research_tags":[107,109],"class_list":["post-20794","news_research","type-news_research","status-publish","hentry","news_research_categories-project","news_research_tags-adrenoleukodystrophy","news_research_tags-x-linked-adrenoleukodystrophy"],"acf":[],"yoast_head":"\nEvaluating glial and neuronal GFAP, MCP-1 and NfL as blood biomarkers for onset and disease severity in cerebral adrenoleukodystrophy - ELA International<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/elainternational.eu\/en\/actualites_recherche\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaluating glial and neuronal GFAP, MCP-1 and NfL as blood biomarkers for onset and disease severity in cerebral adrenoleukodystrophy - ELA International\" \/>\n<meta property=\"og:url\" content=\"https:\/\/elainternational.eu\/en\/actualites_recherche\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\/\" \/>\n<meta property=\"og:site_name\" content=\"ELA International\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-11T09:53:34+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/elainternational.eu\\\/en\\\/actualites_recherche\\\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\\\/\",\"url\":\"https:\\\/\\\/elainternational.eu\\\/en\\\/actualites_recherche\\\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\\\/\",\"name\":\"Evaluating glial and neuronal GFAP, MCP-1 and NfL as blood biomarkers for onset and disease severity in cerebral adrenoleukodystrophy - ELA International\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/elainternational.eu\\\/en\\\/#website\"},\"datePublished\":\"2024-06-25T06:51:21+00:00\",\"dateModified\":\"2024-07-11T09:53:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/elainternational.eu\\\/en\\\/actualites_recherche\\\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/elainternational.eu\\\/en\\\/actualites_recherche\\\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/elainternational.eu\\\/en\\\/actualites_recherche\\\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/elainternational.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaluating glial and neuronal GFAP, MCP-1 and NfL as blood biomarkers for onset and disease severity in cerebral adrenoleukodystrophy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/elainternational.eu\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/elainternational.eu\\\/en\\\/\",\"name\":\"ELA International\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/elainternational.eu\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaluating glial and neuronal GFAP, MCP-1 and NfL as blood biomarkers for onset and disease severity in cerebral adrenoleukodystrophy - ELA International","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/elainternational.eu\/en\/actualites_recherche\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\/","og_locale":"en_US","og_type":"article","og_title":"Evaluating glial and neuronal GFAP, MCP-1 and NfL as blood biomarkers for onset and disease severity in cerebral adrenoleukodystrophy - ELA International","og_url":"https:\/\/elainternational.eu\/en\/actualites_recherche\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\/","og_site_name":"ELA International","article_modified_time":"2024-07-11T09:53:34+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/elainternational.eu\/en\/actualites_recherche\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\/","url":"https:\/\/elainternational.eu\/en\/actualites_recherche\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\/","name":"Evaluating glial and neuronal GFAP, MCP-1 and NfL as blood biomarkers for onset and disease severity in cerebral adrenoleukodystrophy - ELA International","isPartOf":{"@id":"https:\/\/elainternational.eu\/en\/#website"},"datePublished":"2024-06-25T06:51:21+00:00","dateModified":"2024-07-11T09:53:34+00:00","breadcrumb":{"@id":"https:\/\/elainternational.eu\/en\/actualites_recherche\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/elainternational.eu\/en\/actualites_recherche\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/elainternational.eu\/en\/actualites_recherche\/evaluating-glial-and-neuronal-gfap-mcp-1-and-nfl-as-blood-biomarkers-for-onset-and-disease-severity-in-cerebral-adrenoleukodystrophy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/elainternational.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Evaluating glial and neuronal GFAP, MCP-1 and NfL as blood biomarkers for onset and disease severity in cerebral adrenoleukodystrophy"}]},{"@type":"WebSite","@id":"https:\/\/elainternational.eu\/en\/#website","url":"https:\/\/elainternational.eu\/en\/","name":"ELA International","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/elainternational.eu\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/elainternational.eu\/en\/wp-json\/wp\/v2\/news_research\/20794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/elainternational.eu\/en\/wp-json\/wp\/v2\/news_research"}],"about":[{"href":"https:\/\/elainternational.eu\/en\/wp-json\/wp\/v2\/types\/news_research"}],"author":[{"embeddable":true,"href":"https:\/\/elainternational.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"wp:attachment":[{"href":"https:\/\/elainternational.eu\/en\/wp-json\/wp\/v2\/media?parent=20794"}],"wp:term":[{"taxonomy":"news_research_categories","embeddable":true,"href":"https:\/\/elainternational.eu\/en\/wp-json\/wp\/v2\/news_research_categories?post=20794"},{"taxonomy":"news_research_tags","embeddable":true,"href":"https:\/\/elainternational.eu\/en\/wp-json\/wp\/v2\/news_research_tags?post=20794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}